Connect with us

Legal & Regulation

Rep. Greg Steube’s “Marijuana 1-to-3 Act” to Boost Cannabis Research Efforts, Move to Schedule III Classification

Published

on

Rep. Greg Steube Introduces “Marijuana 1-to-3 Act” to Increase Cannabis Research Efforts

On Thursday, September 12, Rep. Greg Steube introduced the “Marijuana 1-to-3 Act,” to the legislation reports MarijuanaMoment. This bill would require the attorney general to de-schedule cannabis from Schedule I of the Controlled Drugs and Substances Act and instead place it under Schedule III of the act.

As per Steube, the reason for doing so stems from the fact that medical marijuana is now legal in certain states and it only makes sense that the ability to actually study the effect of marijuana, namely its cannabinoids, on human health is maximized. He emphasized that:

“As marijuana is legalized for medical and recreational use across the United States, it is important that we study the effects of the substance and the potential impacts it can have on various populations,” […] “By rescheduling marijuana from a schedule I controlled substance to a schedule III controlled substance, the opportunities for research and study are drastically expanded.”

The entirety of rescheduling marijuana doesn’t only increase researching abilities, but also access to funds, as said individuals or groups can now retort to federal funds depending on the value that comes out of their respective studies. In addition to research, this bill appears to have propositions for marijuana businesses, where they may now be eligible for federal tax deductions.

All that being said, this is the second of a similar type of bill, with a bipartisan bill combining the efforts of Reps. Donna Shalala and Matt Gaetz being the first.

“We hear every day about the positive health benefits of marijuana,” […] “Whether it’s young children with seizure disorders, or veterans suffering from chronic pain, it is clear that there are medical benefits to marijuana and I think it’s time we remove the bureaucratic red tape that prevents us from thoroughly studying this substance.”

The difference between the two bills is that the latter strictly restricts who is deemed a researcher, with universities having the potential to be titled as, “Centers of Excellence in Cannabis Research.” Obviously, Gaetz has also onboarded as a sponsor, which is reasonable as his bill had very comparable goals.

Mrs. Lee, a seasoned Canadian Nurse Practitioner, is pushing 20 plus years working in primary care and has self-identified ‘expertise’ in a number of healthcare-related and wellness-oriented subjects.  With a keen interest in women’s health and family wholeness, combined with a knack for specific clinical condition research, NP Lee continues to lead the TOC CBD medical and scientific editorial team.

Continue Reading

Ultimate CBD Guide


Disclaimer

ultimate-cbd-products-company-guidepopular-cbd-health-benefits best-cannabidiol-guide-resources hemp guide

TimesofCBD is the most active daily CBD news publication featuring the latest cannabis industry stories and marijuana market trends. As the leader in CBD-centric content curation, we invite all readers to come for the headlines and stay for the insights. Quality is the top priority when presenting user guides, analyzing product reviews and reporting fact-checked news announcements. All information is for educational and informational purposes only. Disclaimer.

Got news? Email contact@timesofcbd.com

Copyright © 2020 TimesofCBD.com | Latest CBD News, Cannabis Guides and Marijuana Trends
Note: Always seek real additional medical advice and consultation with a professional healthcare practitioner before considering any CBD. No statements found on this website have underwent Food and Drug Administration evaluation. The efficacy of any products or claims made have never been approved by the FDA either. No products shall ever be intended to diagnose, treat or cure any disease or prevent any ailment.